Effects of a histone deacetylase 3 inhibitor on extinction and reinstatement of cocaine self-administration in rats.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 18 05 2018
accepted: 12 11 2018
pubmed: 30 11 2018
medline: 9 4 2019
entrez: 30 11 2018
Statut: ppublish

Résumé

A challenge in treating substance use disorder is that successful treatment often does not persist, resulting in relapse and continued drug seeking. One approach to persistently weaken drug-seeking behaviors is to pair exposure to drug-associated cues or behaviors with delivery of a compound that may strengthen the inhibition of the association between drug cues and behavior. We evaluated whether a selective histone deacetylase 3 (HDAC3) inhibitor could promote extinction and weaken contextual control of operant drug seeking after intravenous cocaine self-administration. Male Long-Evans rats received a systemic injection of the HDAC3 inhibitor RGFP966 either before or immediately after the first extinction session. Persistence of extinction was tested over subsequent extinction sessions, as well as tests of reinstatement that included cue-induced reinstatement, contextual renewal, and cocaine-primed reinstatement. Additional extinction sessions occurred between each reinstatement test. We also evaluated effects of RGFP966 on performance and motivation during stable fixed ratio operant responding for cocaine and during a progressive ratio of reinforcement. RGFP966 administered before the first extinction session led to significantly less responding during subsequent extinction and reinstatement tests compared to vehicle-injected rats. Follow-up studies found that these effects were not likely due to a performance deficit or a change in motivation to self-administer cocaine, as injections of RGFP966 had no effect on stable responding during a fixed or progressive ratio schedule. In addition, RGFP966 administered just after the first extinction session had no effect during early extinction and reinstatement tests, but weakened long-term responding during later extinction sessions. These results suggest that a systemic injection of a selective HDAC3 inhibitor can enhance extinction and suppress reinstatement after cocaine self-administration. The finding that behavioral and pharmacological manipulations can be combined to decrease drug seeking provides further potential for treatment by epigenetic modulation.

Identifiants

pubmed: 30488346
doi: 10.1007/s00213-018-5122-2
pii: 10.1007/s00213-018-5122-2
pmc: PMC6459190
mid: NIHMS1014896
doi:

Substances chimiques

Acrylamides 0
Histone Deacetylase Inhibitors 0
Phenylenediamines 0
RGFP966 0
Histone Deacetylases EC 3.5.1.98
histone deacetylase 3 EC 3.5.1.98
Cocaine I5Y540LHVR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

517-529

Subventions

Organisme : NIDA NIH HHS
ID : T32 DA007262
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA034388
Pays : United States
Organisme : NIDA NIH HHS
ID : T32DA007262
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA025922
Pays : United States
Organisme : NIDA NIH HHS
ID : P50 DA018165
Pays : United States
Organisme : National Institute on Drug Abuse (US)
ID : R01 025922
Organisme : U.S. Department of Defense (US)
ID : W81XWH-12-2-0048

Références

Learn Mem. 1998 Sep-Oct;5(4-5):365-74
pubmed: 10454361
J Neurosci. 2000 Jan 15;20(2):798-805
pubmed: 10632609
Ann N Y Acad Sci. 2001 Jun;937:1-26
pubmed: 11458532
Behav Neurosci. 2002 Feb;116(1):169-73
pubmed: 11895178
Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
pubmed: 12402102
Neuropsychopharmacology. 2002 Dec;27(6):1006-15
pubmed: 12464457
J Biol Chem. 2004 Apr 9;279(15):15050-8
pubmed: 14722073
Dement Geriatr Cogn Disord. 2004;17(4):277-81
pubmed: 15178936
Neuropsychopharmacology. 2005 Feb;30(2):296-309
pubmed: 15483559
Biol Psychiatry. 2007 Jul 1;62(1):55-64
pubmed: 16945350
Cell. 2007 Feb 23;128(4):693-705
pubmed: 17320507
J Mol Neurosci. 2007;31(1):47-58
pubmed: 17416969
Learn Mem. 2007 Apr 06;14(4):268-76
pubmed: 17522015
J Neurosci. 2007 Jun 6;27(23):6128-40
pubmed: 17553985
Eur J Neurosci. 2007 Aug;26(3):757-66
pubmed: 17651427
Behav Neurosci. 2007 Oct;121(5):1125-31
pubmed: 17907845
Mol Cancer Res. 2007 Oct;5(10):981-9
pubmed: 17951399
J Neurosci. 2008 Sep 17;28(38):9342-8
pubmed: 18799668
Nature. 2009 May 7;459(7243):55-60
pubmed: 19424149
BMC Neurosci. 2009 Aug 07;10:95
pubmed: 19664213
Biol Psychiatry. 2010 Jan 1;67(1):36-43
pubmed: 19765687
PLoS One. 2010 Jan 21;5(1):e8825
pubmed: 20098685
J Neurosci. 2011 Jan 12;31(2):764-74
pubmed: 21228185
Neurobiol Learn Mem. 2011 Jul;96(1):27-34
pubmed: 21521655
Curr Top Behav Neurosci. 2013;13:671-84
pubmed: 21735361
Alcohol Clin Exp Res. 2012 Jan;36(1):61-71
pubmed: 21790673
Anticancer Res. 2011 Sep;31(9):2723-32
pubmed: 21868513
Curr Neuropharmacol. 2011 Mar;9(1):21-5
pubmed: 21886555
Biol Psychiatry. 2012 Jul 1;72(1):25-33
pubmed: 22290116
Neuropharmacology. 2013 Jan;64:414-23
pubmed: 22722028
Neuropsychopharmacology. 2013 Jan;38(1):3-22
pubmed: 22828751
Pharmacol Biochem Behav. 2012 Dec;103(2):373-9
pubmed: 23026056
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52
pubmed: 23297220
Pharmacol Biochem Behav. 2013 May;106:109-16
pubmed: 23454534
PLoS One. 2013;8(3):e57816
pubmed: 23469244
J Neurosci. 2013 Apr 10;33(15):6623-32
pubmed: 23575859
Psychopharmacology (Berl). 2013 Oct;229(3):453-76
pubmed: 23685858
Br J Haematol. 2013 Aug;162(4):498-508
pubmed: 23758082
Nucleic Acids Res. 2013 Sep;41(17):8072-84
pubmed: 23821663
Protein Sci. 2013 Oct;22(10):1306-12
pubmed: 23904210
Depress Anxiety. 2014 Apr;31(4):279-90
pubmed: 24254958
Prog Mol Biol Transl Sci. 2014;122:305-40
pubmed: 24484706
Eur J Pharmacol. 2014 Mar 15;727:80-6
pubmed: 24486700
Behav Brain Res. 2014 May 15;265:61-8
pubmed: 24525423
Behav Processes. 2014 May;104:13-9
pubmed: 24576702
Neurobiol Learn Mem. 2014 May;111:1-8
pubmed: 24583371
Biochem Soc Trans. 2014 Apr;42(2):569-81
pubmed: 24646280
Behav Neurosci. 2014 Apr;128(2):217-27
pubmed: 24773441
J Mol Neurosci. 2015 Jan;55(1):269-278
pubmed: 24829091
J Physiol Paris. 2014 Sep-Dec;108(4-6):278-85
pubmed: 24978317
Addict Biol. 2015 Jul;20(4):676-89
pubmed: 25041570
Mol Psychiatry. 2015 Oct;20(10):1219-31
pubmed: 25288139
Prog Mol Biol Transl Sci. 2014;128:51-87
pubmed: 25410541
Front Mol Neurosci. 2014 Nov 12;7:86
pubmed: 25429258
Sci Signal. 2014 Dec 09;7(355):re12
pubmed: 25492968
Hippocampus. 2015 Jul;25(7):827-37
pubmed: 25530477
Pharmacol Ther. 2015 May;149:150-90
pubmed: 25550231
Int J Neuropsychopharmacol. 2015 Mar 11;18(9):null
pubmed: 25762717
Learn Mem. 2015 Mar 16;22(4):225-31
pubmed: 25776040
PLoS One. 2015 Apr 16;10(4):e0124796
pubmed: 25880762
CNS Neurol Disord Drug Targets. 2015;14(6):764-72
pubmed: 26022264
J Neurosci. 2015 Sep 23;35(38):13124-32
pubmed: 26400942
Prog Brain Res. 2016;224:25-52
pubmed: 26822352
Nat Neurosci. 2016 Nov;19(11):1497-1505
pubmed: 27428650
Transl Psychiatry. 2016 Dec 6;6(12):e974
pubmed: 27922638
Neurobiol Learn Mem. 2017 Nov;145:94-104
pubmed: 28890149
Front Syst Neurosci. 2017 Sep 05;11:65
pubmed: 28928640
Hippocampus. 2018 Mar;28(3):226-238
pubmed: 29341327
Biol Psychiatry. 2018 Sep 1;84(5):383-392
pubmed: 29571524
Pharmacol Biochem Behav. 1993 Jul;45(3):539-48
pubmed: 8332614
J Neurosci Methods. 1996 May;66(1):1-11
pubmed: 8794935
Psychopharmacology (Berl). 1998 Jan;135(2):151-60
pubmed: 9497020

Auteurs

Leah N Hitchcock (LN)

Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR, USA.

Jonathan D Raybuck (JD)

Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR, USA.

Marcelo A Wood (MA)

Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA.

K Matthew Lattal (KM)

Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR, USA. lattalm@ohsu.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH